Arbutus Biopharma CorporationABUSNASDAQ
LOADING
|||
Cash Flow Performance
Trending higher, above historical average, structural decline.
Left:
||||
Free cash flow yield
Latest
-10.71%
↑ 57% above average
Average (9y)
-25.14%
Historical baseline
Range
High:-10.20%
Low:-47.61%
CAGR
-10.2%
Structural decline
| Period | Value | Change |
|---|---|---|
| 2024 | -10.71% | +48.9% |
| 2023 | -20.96% | -105.5% |
| 2022 | -10.20% | +38.3% |
| 2021 | -16.54% | +13.8% |
| 2020 | -19.19% | +57.5% |
| 2019 | -45.11% | -38.4% |
| 2018 | -32.59% | -61.2% |
| 2017 | -20.23% | +57.5% |
| 2016 | -47.61% | -68.7% |
| 2015 | -28.22% | - |